Dietary Ingredient Derived from Animals in Texas Feed Yards to Help Promote Health
Amarillo, Texas, May 28, 2010 — Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) today announced that Maxisal, its dietary supplement to enhance salivary function, promote oral comfort and help relive dry mouth, has been launched in Germany (www.Maxisal.de). Maxisal is marketed in Germany by ABI’s licensee Egofocus OHG based in Darmstadt. The first target market in Germany is cancer patients. There are over 400 medications, including some oncology drugs, that cause dry mouth as a severe side effect. By taking Maxisal, cancer patients may be able to relieve at least one of the side effects of cancer therapy. Maxisal was first offered for sale after clinical studies in subjects with Sjogren’s syndrome (characterized by dry eyes and dry mouth) reported that the ingredient in Maxisal significantly improved mouth comfort and decreased mouth and throat dryness.
“Based on the favorable reception Maxisal has met in the U.S.,--which we attribute to the product’s clinical and safety benefits, as well as reasonable cost-- we fully expect that it will be successful in Germany, said Dr. Joseph Cummins, President and CEO, ABI.
Separately, the company announced that it has prepared a dietary ingredient for natural food distributors to market as a dietary supplement. The ingredient is derived from animals in the feed yards of the Texas Panhandle.
“After more than 30 years of experience testing cytokines, in animals and man, we have developed a novel dietary ingredient derived from ruminant animals,” said Dr. Joseph Cummins, “We are seeking distributors of dietary supplements worldwide and have initiated discussions in the USA, China, and South America. The animal product will be available in June and revenues from both of the dietary supplements are expected to help the Company fund its FDA clinical trials of oral human interferon in influenza and hepatitis C,” added Dr. Cummins.
About Amarillo Biosciences
Amarillo Biosciences, Inc. is a U.S. biotechnology firm operating in global partnership with the Hayashibara Group, which also holds 6% of Amarillo Biosciences shares and has provided over $18 million in loans, grants and equity investments. The Company's primary focus is extensive and ongoing R&D into the use of low-dose, orally administered interferon as a treatment for a variety of conditions, including influenza, hepatitis C, chronic cough, and opportunistic infections in patients who are HIV positive. The Company has invested nearly $40 million to establish oral interferon as a therapeutic agent. The majority of those funds were invested in clinical trials in an effort to achieve FDA approval for interferon. Additional information is available on the web at http://www.amarbio.com/.
Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of oral interferon or the Company’s other product candidates and other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission. In particular, see “Item 1. Description of Business” and “Item 7A. Qualitative and Quantitative Disclosures About Market Risk” of the Company’s Form 10-K for the fiscal year ended December 31, 2009. --END--